Rouvas A, et al. - In a follow-up time of 12 months, experts compared the effectiveness and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) because of age-related macular degeneration (AMD). Aflibercept illustrated superiority to ranibizumab in terms of best-corrected visual acuity (BCVA) improvement. However, both agents demonstrated anatomical effectiveness with a marked reduction in pigment epithelium detachment (PED) height and subretinal fluid (SRF) absorption in the study cohort.